Drug Interaction With Genes in Parkinson's Disease (DIGPD)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01564992 |
Recruitment Status : Unknown
Verified July 2018 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was: Recruiting
First Posted : March 28, 2012
Last Update Posted : August 13, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Parkinson's Disease | Other: Identification of genes |
Title : Drug interaction with genes in Parkinson Disease
Objective:
To identify genes associated to disease and treatment complication and response.
Number of subjects: 500
Study duration : 6 years
Design:
Prospective cohort with biological collection
Primary objective:
Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.
Secondary objectives:
- Prevalence and incidence of disease or treatment complications
- Clinical risk factor for disease or treatment complications
- Biomarkers of disease progression, disease or treatment complications
Study Type : | Observational |
Estimated Enrollment : | 600 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Drug Interaction With Genes in Parkinson's Disease |
Actual Study Start Date : | May 2009 |
Estimated Primary Completion Date : | June 2019 |
Estimated Study Completion Date : | July 2019 |

Group/Cohort | Intervention/treatment |
---|---|
Parkinson disease
Identification of genes
|
Other: Identification of genes
Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.
Other Name: polymorphism or haplotype |
- All complications of the disease or treatment [ Time Frame: 5 years ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Men and women, age > 18.
- Parkinson Disease according to UKPDSBB criteria
- PD diagnosis < 6 years
- Informed consent
Exclusion Criteria:
- Atypical parkinsonism

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01564992
Contact: Jean-Christophe Corvol, MD, PhD | +33 1 42 16 57 66 |
France | |
Centre d'Investigation Clinique Neuro - Bâtiment ICM - Hôpital Pitié-Salpêtrière | Recruiting |
Paris, France, 75013 | |
Contact: Jean-Christophe Corvol, MD, PhD +33 1 42 16 57 66 | |
Principal Investigator: Jean-Christophe Corvol, MD, PhD |
Principal Investigator: | Jean-Christophe Corvol, MD, PhD | Asssitance Publique - Hopitaux de Paris |
Responsible Party: | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT01564992 |
Other Study ID Numbers: |
P 071240 |
First Posted: | March 28, 2012 Key Record Dates |
Last Update Posted: | August 13, 2018 |
Last Verified: | July 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Parkinson's disease Pharmacogenetics Genetics |
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Movement Disorders Synucleinopathies Neurodegenerative Diseases |